We follow and summarise scientific research into cell-based approaches studied in the context of COVID-19. This page is for information and education only. It is not medical advice and not an offer of any treatment or rehabilitation. Cell-based approaches in COVID-19 are investigational and are not authorised treatments.
In addition to standard therapies related to the treatment of COVID-19, there is supporting evidence for adjuvant therapy to reduce mortality rates and improve recovery after treatment. Thus, MSC treatment may be considered as a potential candidate for adjuvant therapy in moderate to severe cases of COVID-19. www.nature.com/articles/s41536-021-00181-9
Infusions of human umbilical cord-derived mesenchymal stem cells (MSCs) to COVID-19 patients with acute respiratory distress syndrome (ARDS) may reduce cytokine storm and lung damage.
www.nature.com/articles/s41536-021-00161-z
In patients with comorbidities, UC-MSC administration increased survival by 4.5 times compared with controls. Length of stay in intensive care and use of a ventilator were not statistically significant, and no side effects were reported. UC-MSC infusion significantly reduced interleukin 6 levels in recovered patients (P = 0.023). Therefore, the use of intravenous UC-MSCs as an adjuvant treatment for critically ill patients with COVID-19 increases survival by modulating the immune system towards an anti-inflammatory state. www.stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.21-0046
